Vertex Pharmaceuticals is pressing pause on a phase 1/2 cystic fibrosis (CF) trial over a tolerability issue while reporting ...

Vertex Pharmaceuticals missed first-quarter profit and revenue forecasts as costs jumped. The biotech firm also posted a ...

One positive sign was that Vertex raised the lower end of its forecast for full-year 2025 revenue by $100 million. The ...

Intangible asset impairment charge of $379.0 million associated with VX-264 (the “cells plus device” program) in patients with type 1 diabetes, which will not be advancing further in clinical ...

In addition, it also had a $379.0 million intangible asset impairment charge associated with its experimental diabetes treatment VX-264, which it won't be advancing for additional clinical ...

The company said it would not be advancing further in VX-264 clinical trials. Vertex plans to conduct further analyses, including of explanted devices. Vertex Pharmaceuticals shares gained 0.5% to ...

Even worse was the fact that adjusted earnings excluded a $379 million asset impairment charge that stemmed from the decision not to advance Vertex's VX-264 program for patients with type 1 diabetes.

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat ...